New Enhancing CLIA Act: What Lab Directors Need to Know
The proposal seeks to move any future LDT authority away from the FDA
Already a member? Log in here
Essential
Subscribe today for access to
Articles and Reports
How to Stay Ahead of Anticipated CLIA Deficiencies
Consultant Nora Hess offers suggestions for clinical labs to navigate these problems
Already a member? Log in here
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
Study Questions Billing for Part B Laboratory Services
...
Already a member? Log in here
News-At-A-Glance: Optim Healthcare Agrees to $4 Million Settlement
...
Already a member? Log in here
News-At-A-Glance: Noridian Issues Molecular and Genetic Test LCDs
...
Already a member? Log in here
News-At-A-Glance: Program Transmittal Meant to Clarify Homebound Definition
...
Already a member? Log in here
Compliance Corner
...
Already a member? Log in here
Arizona Hospital Network Agrees to $35 Million FCA Settlement
...
Already a member? Log in here
Comparative Billing Report Identifies Special Stain Outliers
...
Already a member? Log in here
Compliance Priorities for Laboratory-Developed Tests
...
Already a member? Log in here